Home

Waqqas Afif

Academic title(s): 

Associate Professor, Department of Medicine, McGill University

Waqqas Afif
Contact Information
Address: 

Montreal General Hospital

1650 Cedar Avenue, Room #C7-200

Montreal, QC H3G 1A4

Phone: 
514-934-8309
Position: 
MGH Site Director
Degree(s): 

MD, M.Sc., FRCPC

Areas of expertise: 

Inflammatory Bowel Disease

Selected publications: 

1. Restellini S, Khanna R, Afif W: Therapeutic Drug Monitoring With Ustekinumab and Vedolizumab in Inflammatory Bowel Disease. Inflamm Bowel Dis. 2018 Sep 15;24(10):2165-2172.

2. Nguyen GC, Murthy SK, Bressler B, Lam MCW, Alali A, Toumi A, Reinglas J, Rampersad A, Weizman AV, Afif W; CINERGI group. Quality of care and outcomes among hospitalized inflammatory bowel disease patients: A Multicenter Retrospective Study. Inflamm Bowel Dis. 2017 May;23(5):695-701.

3. Battat R, Kopylov U, Bessissow T, Bitton A, Cohen A, Jain A, Martel M, Seidman E, Afif W. Association between ustekinumab trough concentrations and clinical, biomarker, and endoscopic outcomes in patients With Crohn's disease. Clin Gastroenterol Hepatol. 2017 Sep;15(9):1427-1434.e2.

4. Afif W, Sandborn WJ, Faubion WA, Rahman M, Harmsen SW, Zinsmeister AR, Loftus EV Jr. Risk factors for lymphoma in patients with inflammatory bowel disease: a case-control study. Inflamm Bowel Dis. 2013 Jun;19(7):1384-9.

5. Afif W, Loftus EV Jr, Faubion WA, Kane SV, Bruining DH, Hanson KA, Sandborn WJ.Clinical utility of measuring infliximab and human anti-chimeric antibody concentrations in patients with inflammatory bowel disease. Am J Gastroenterol. 2010 May;105(5):1133-9.

Location: 
MUHC, Montreal General Hospital
Back to top